Partner Headlines - BMRN

  1. Rayno Biobeat #4: Sector Shift Underway But What’s Next For Biotech? ...

    TalkMarkets
  2. Stock Exchange: Is Technical Analysis Effective Post-Election?

    TalkMarkets
  3. Biogen Upgraded To Overweight From Neutral At Piper Jaffray

    TalkMarkets
  4. Weighing the Week Ahead: Time for Some Clarity?

    TalkMarkets
  5. Stock Exchange: Contrarian Pre-Election Trade Ideas In Chips, ...

    TalkMarkets
  6. Contrarian Pre-Election Trade Ideas In Chips, Biotech, Trucking, ...

    TalkMarkets
  7. Seattle Genetics (SGEN) Loss Narrower Than Expected In Q3

    TalkMarkets
  8. J&J Outshines in Q3 Earnings on Strong Pharma Sales

    TalkMarkets
  9. Swing Trading Watch List - October 11, 2016

    TalkMarkets
  10. Sarepta Stock Slides As FDA Sends Another Bad Signal On DMD

    IBD
  11. Roche Holdings Definitely Not a Lumbering Giant

    GuruFocus
  12. The FDA Just Crushed Sarepta Therapeutics' Hopes Of Releasing ...

    Benzinga
  13. Sarepta Plummets As FDA Slams Muscular Dystrophy Drug

    IBD
  14. BioMarin Muscular Dystrophy Drug Rejected By FDA

    IBD
  15. BioMarin Announces Interim Analysis of INSPIRE Clinical Trial ...

    Benzinga
  16. BioMarin, Intercept hit by FDA

    IBD
  17. BioMarin, Intercept Pharma Drugs Face FDA Delays

    IBD
  18. BioMarin Announces That FDA Has Advised it Will Not Take Action ...

    Benzinga
  19. Pharmaceutical Stocks Hold Prominent Positions in Kyle Bass' ...

    GuruFocus
  20. FDA Panel Seen As Bad For BioMarin, Good For Sarepta

    IBD
  21. FDA Advisory Committee Discusses Clinical Data Package for BioMarin's ...

    Benzinga
  22. BioMarin Drug's Future In Doubt After FDA Panel Vote

    IBD
  23. BIOMARIN PHARMA

    IBD
  24. KaloBios, Valeant Lead Week's 5 Top Drug Stock Gainers

    IBD
  25. Here's Why Sarepta Is Skyrocketing While BioMarin Is Falling

    Benzinga
  26. Morning Market Losers

    Benzinga
  27. Benzinga's Top #PreMarket Losers

    Benzinga
  28. Goldman Sachs' Top 4 Smid-Cap Biotech Picks

    IBD
  29. Benzinga's Top Initiations

    Benzinga
  30. Biotech ETFs: Buy, Buy, Buy?

    Benzinga
  31. Hurricane Hillary Shifts Left, Slamming More Stocks

    IBD
  32. PTC Stock Seesaws On Muscular Dystrophy Drug Data

    IBD
  33. BioMarin's Initial 6-Month Data From Phase 2 Study of Vosoritide ...

    Benzinga
  34. Sarepta Stock Soars On New Muscular-Dystrophy Data

    IBD
  35. BioMarin to Acquire Rights to Phenylketonuria (PKU) Franchise ...

    Benzinga
  36. Wednesday's After-Hours Movers: PBF Energy, BioMarin Pharmaceutical ...

    Benzinga
  37. Stocks Rally, Will Gains Hold? Biotechs Try Second Rebound

    IBD
  38. Benzinga's Top #PreMarket Losers

    Benzinga
  39. Amgen And Biogen Lead Short Interest Surge In Biotechs

    Benzinga
  40. BioMarin Announces Two Oral and 19 Poster Presentations at the ...

    Benzinga
  41. Medivation to Expand Global Oncology Franchise With the Acquisition ...

    GuruFocus
  42. Benzinga's M&A Chatter for Monday August 24, 2015

    Benzinga
  43. Medivation to Expand Global Oncology Franchise With the Acquisition ...

    Benzinga
  44. BioMarin Receives Rare Pediatric Disease Designation From FDA ...

    Benzinga
  45. BioMarin Gets Price Target Hike On Pipeline Strength

    IBD
  46. 2 DMD drugs make progress

    IBD
  47. BioMarin, Sarepta Muscular Dystrophy Drugs Progress

    IBD
  48. Baird Downgrades BioMarin Pharmaceutical To Neutral

    Benzinga
  49. Benzinga's Volume Movers

    Benzinga
  50. Benzinga's Top Downgrades

    Benzinga
  51. Mid-Afternoon Market Update: BioMarin Pharmaceutical Jumps Following ...

    Benzinga
  52. Mid-Day Market Update: Oracle Drops On Downbeat Results; Radius ...

    Benzinga
  53. BioMarin Stock Hits High On Dwarfism Drug Success

    IBD
  54. Mid-Morning Market Update: Markets Open Higher; Kroger Earnings ...

    Benzinga
  55. Benzinga's Volume Movers

    Benzinga
  56. Morning Market Gainers

    Benzinga
  57. Dollar, Data Boost Stock Futures; Oracle Tumbles, Taser Gains

    IBD
  58. Benzinga's Top #PreMarket Gainers

    Benzinga
  59. BIOMARIN PHARMA

    IBD
  60. Pier 1, BioMarin, HomeAway & Oracle Lead Wednesday's After-Hours ...

    Benzinga
  61. BMN 111 (vosoritide) Improves Growth Velocity in Children With ...

    Benzinga
  62. BioMarin Submits Drisapersen MAA to EMA for the Treatment of ...

    Benzinga
  63. Benzinga's Top Initiations

    Benzinga
  64. Barclays Initiates BioMarin Pharmaceutical With Overweight

    Benzinga
  65. Sarepta Soars On New Hope For Muscular-Dystrophy Drug

    IBD
  66. Alexion's $8.4 Billion Synageva Buyout Spooks Street

    IBD
  67. BIOMARIN PHARMA

    IBD
  68. BioMarin Completes Rolling NDA Submission to FDA for Drisapersen ...

    Benzinga
  69. J.P. Morgan's 3 Biotechnology Picks

    GuruFocus
  70. What Evercore Is Watching At BioMarin Pharmaceutical

    Benzinga
  71. BioMarin To Report Revenue In-line With Consensus, Wedbush Says

    Benzinga
  72. Why Muscular Dystrophy Is Biotech's Favorite Orphan

    IBD
  73. Bank Of America Upgrades Sarepta Therapeutics On 'Increased Conviction' ...

    Benzinga
  74. Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea

    IBD
  75. BIOMARIN PHARMA

    IBD
  76. State Of The Union Lights Up Biotech

    Benzinga
  77. Nomura Analyst Sees Fast Growth At BioMarin Pharmaceutical

    Benzinga
  78. UPDATE: Nomura Raises Price Target On BioMarin Pharmaceutical ...

    Benzinga
  79. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  80. Regeneron Jumps On Favorable Cholesterol Drug Report

    IBD
  81. 5 Potential Blockbuster Drugs Set To Launch In 2015

    IBD
  82. What Investors Are Looking For In NPS Pharmaceuticals Ahead Of ...

    Benzinga
  83. BioMarin CEO Sees Big Future For Prosensa Drug

    IBD
  84. UPDATE: UBS Securities Reiterates On BioMarin Pharmaceutical ...

    Benzinga
  85. FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion ...

    Benzinga
  86. BioMarin Will Report Breadth of Innovative Development Pipeline ...

    Benzinga
  87. Benzinga's M&A Chatter for Monday November 24, 2014

    Benzinga
  88. BioMarin buying Prosensa

    IBD
  89. Trio Of Major Deals Disclosed

    IBD
  90. Mid-Afternoon Market Update: Trina Solar Drops After Quarterly ...

    Benzinga
  91. Mid-Day Market Update: Dow Edges Lower; Platinum Underwriters ...

    Benzinga
  92. Mid-Morning Market Update: Markets Open Higher; BioMarin To Acquire ...

    Benzinga
  93. Benzinga's Volume Movers

    Benzinga
  94. BioMarin Buying Prosensa, Backing Up Troubled Drug

    IBD
  95. Stocks Hitting 52-Week Highs

    Benzinga
  96. Morning Market Movers

    Benzinga
  97. Stock Futures Trending Higher; Kate Spade Bags An Upgrade

    IBD
  98. BioMarin Pharmaceuticals To Acquire Prosensa

    Benzinga
  99. Benzinga's Top #PreMarket Gainers

    Benzinga
  100. US Stock Futures Up Ahead Of Economic Data

    Benzinga
Trading Center